GLP1R and type 1 diabetes mellitus: Further studies are also needed to establish definitions and clinical thresholds for indices of HbA1c variability, as well as to confirm whether targeting long-term glycaemic variability using new technology and add-on medications, such as GLP-1 receptor agonists and SGLT2 inhibitors, will reduce the cardiovascular risk for individuals with type 1 diabetes.